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METHOD FOR TREATING A VIRAL 
INFECTION RELATED OR A CHEMICAL 
TOXIN RELATED HEPATIC INJURY WITH 
DELTORPHIN D 
This application is a divisional of US. application Ser. 
No. 09/971,902, ?led Oct. 5, 2001 now US. Pat. No. 
6,875,742, Which claims the bene?t of US. application Ser. 
No. 60/238,991, ?led Oct. 10, 2000, the disclosures ofWhich 
are hereby incorporated by reference herein in their entirety. 
FIELD OF THE INVENTION 
The invention relates to the use of compounds to attenuate 
or prevent cytokine mediated hepatic injury. 
BACKGROUND 
Hepatic injury can be caused by a number of different 
agents including viruses such as Hepatitis A, B, C, D and E, 
both gram positive and gram negative bacteria, chemical 
agents such as ethanol, carbon tetrachloride and lead, and by 
physical trauma resulting in ischemia (ischemic hepatitis) 
injuries as can occur in right-sided congestive heart failure. 
It is noW believed that all of these types of hepatic injury are 
caused at least in part by the liver’s in?ammatory or cytok 
ine response to these agents. The in?ammatory response of 
the liver results in the overexpression of a cascade of 
in?ammatory/acute phase cytokines, such as interleukin-1 
(IL-1), tumor necrosis factor (TNF), IL-6, IL-8 and trans 
forming groWth factor beta (TGFB). It is noW believed that 
it is the cascade of these cytokines Which is the ultimate 
cause of much of the hepatic injury resulting from these 
agents. Thus, there is a need for a therapeutic agent Which 
can be useful in alleviating or modulating the in?ammatory 
response associated With liver disease or injury. 
SUMMARY OF THE INVENTION 
The present invention ?lls this need by providing a 
method of treating or preventing a cytokine mediated 
hepatic injury in a mammal comprised of administering a 
pharmaceutically effective amount of a peptide having the 
sequence Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile 
Gly-Asp-Phe-Phe-His-Ser-Ile-NH2 SEQ ID NO: 1, herein 
after referred to as compound D, to said mammal. The 
hepatic injury can be an acute in?ammatory reaction, as a 
result of a viral or bacterial infection or a chemical agent 
such as ethanol, lead, carbon tetrachloride or acetami 
nophen, or from trauma resulting in ischemia or reperfusion 
injury in the liver. 
The present invention is also directed to a method of 
treating a viral or bacterial infection-related hepatic damage 
in a mammal comprised of administering a pharmaceutically 
effective amount of compound D SEQ ID NO: 1 to said 
mammal. 
The present invention is also directed to a method of 
treating alcohol induced liver injury in a mammal comprised 
of administering a pharmaceutically effective amount of 












Preferably, compound D SEQ ID NO:1 is administered in 
a pharmaceutical composition at a dosage of from about 0.5 
mg/kg to about 20 mg/kg per body Weight of the mammal. 
Preferably, the mammal is a human. 
DETAILED DESCRIPTION 
A compound used to treat cytokine-mediated hepatic 
injury is a peptide having the sequence Tyr-D-Leu-Phe-Ala 
Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile 
NH2 SEQ ID NO: 1, hereinafter referred to compound-D. The 
peptide may be produced by a number of methods, such as 
using an automated peptide synthesiZer, through recombi 
nant molecular techniques, or isolated from a naturally 
occurring source, as is knoWn to one skilled in the art. 
Compound-D SEQ ID NO:1 has a molecular Weight of 
1,902 daltons. Compound-D SEQ ID NO:1 is insoluble in 
Water or saline, but may be solubiliZed by adding 100 uM of 
a solution comprised of ethanol, propylene glycol, and 1 N 
NaOH in a 1:1:1 ratio, With sterile physiological saline then 
used to obtain the appropriate concentration. The initial 
alkaline pH is adjusted to 7.4 With 1 N HCl. 
Compound-D SEQ ID NO:1 that has been solubiliZed 
may be administered by parenteral means, for example, by 
intravenous injection. For administration into a mammal, a 
dose of about 1-20 milligrams per kilogram (mg/kg) is 
useful. For administration into a tissue or organ preservation 
solution, a concentration of about 100 uM is useful. 
Compound-D SEQ ID NO:1 may be administered directly 
into a mammal, either alone or in combination With other 
substances. 
The above agent is administered to a mammal to modulate 
cytokine activation by blocking one or more steps in the 
cytokine cascade. The agent may be formulated for admin 
istration in an aqueous based liquid such as phosphate 
buffered saline to form an emulsion, or may be formulated 
in an organic liquid such as dimethylsulfoxide to form a 
solution. The solution or emulsion may be administered by 
any route, but it is preferably administered parenterally such 
as by intravenous, intramuscular, intradermal or intraperi 
toneal injections. A preferred dose is in the range of about 
0.5-20 mg of compound-D SEQ ID NO:1 per kg of body 
Weight of the mammal. The time of administration of the 
agent is preferably prior to initiation of cytokine activation. 
HoWever, the agent may be administered concurrently With 
another agent that induces cytokine activation or even 
subsequent to an agent that induces cytokine activation and 
still produce a protective effect. 
Administration of compound-D SEQ ID NO:1 should be 
continued on a daily basis until hepatic function returns to 
normal and is maintained at normal levels, preferably for at 
least one to tWo days. Hepatic injury can be determined by 
elevated levels of hepatic enZymes, as Well as by depressed 
albumin levels (less than about 35 g/liter). Hepatic function 
is routinely monitored by quantitating serum levels of 
hepatic enZymes such as alanine aminotransferase (ALT) 
(normal<35 U/L), aspartate aminotransferase (AST) (nor 
mal<30 U/L), alkaline phosphatase (ALP) (normalé100 
US 7,335,642 B2 
3 
U/L) and gamma glutamyltransferase (GGT) (normalé45 
U/L for males, E30 U/L for females), as Well as bilirubin, 
both conjugated (normal§0.2 mg/deciliter) and total (nor 
mal§1.0 mg/deciliter) bilirubin. Compound-D SEQ ID 
4 
Therefore various changes, modi?cations or alterations to 
these embodiments may be made or resorted to Without 
departing from the spirit of the invention and the scope of 
the following claims. 
SEQUENCE LISTING 
SEQ ID NO 1 
LENGTH: 17 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
NAME/KEY: MODiRES 
LOCATION: (l) . . . (17) 
OTHER INFORMATION: Xaa = 
synthesized 
D-Leu; 
<400> SEQUENCE: l 
artificial sequence is completely 
Tyr Xaa Phe Ala Asp Val Ala Ser Thr Ile Gly Asp Phe Phe His Ser Ile 
l 5 l0 
NOzl modulation of hepatocyte cytokine activation may be 
used therapeutically in a variety of hepatic injury processes. 
As used herein, the term hepatic injury broadly encompasses 
all types of injury such as hepatic trauma, physical and/or 
chemical insult, stress, in?ammation, toxicity, disease and so 
on. For example, the inventive agents can be used in treating 
hepatic injury due to alcoholic liver disease, acetaminophen 
toxicity, cadmium toxicity, lead poisoning, bacteremia due 
to, for example, Staphylococcus species, Streptococcus spe 
cies, Neisseria species, Salmonella species, Shigella species, 
Escherichia coli, Clostridium perfringens, Klebsiella spe 
cies, Proteus species, Enterobacter species, Bacteroides 
species, Brucella species, Francisella tularensis, Listeria 
monocytogenes, Acinetobacter species, Streptobacillus 
moniliformis, Vlbl’lO species, Helicobacter pylori, 
Pseudomonas species, Haemophilus species, Bordetella per 
tussis, viral infections due to, for example, in?uenza viruses, 
adenoviruses, paramyxoviruses, rubella viruses, poliovi 
ruses, hepatitis viruses, herpesviruses, rabies viruses, human 
immunode?ciency viruses and papilloma viruses, as Well as 
trauma, ischemia reperfusion injury and metabolic liver 
disease. 
While the speci?c mechanism of action of compound-D 
SEQ ID NO:1 on the modulation of cytokine mediated 
hepatic injury such as acute in?ammatory reactions, trauma 
and toxin induced biological responses is unknown, these 
agents exhibit a speci?c and reproducible effect on decreas 
ing hepatotoxicity. 
A treatment for attenuating and/or preventing cytokine 
mediated acute in?ammatory, trauma induced and toxin 
induced hepatic injury is thus disclosed. Compound-D SEQ 
ID NO: 1, administered at a concentration of about 0.5 mg/kg 
to about 20 mg/kg, inhibits hepatic injury and result in 
decreased lethality of an injured animal. 
It should be understood that the embodiments of the 
present invention shoWn and described in the speci?cation 
are only preferred embodiments of the inventors Who are 










What is claimed is: 
1. A method for treating a viral infection related hepatic 
injury in a mammal comprising administering a pharmaceu 
tically effective concentration of the peptide shoWn in SEQ 
ID NO:1 for a duration su?icient to treat the hepatic injury 
related to the viral infection. 
2. The method of claim 1 Wherein the viral infection is 
caused by a hepatitis virus. 
3. The method of claim 1 Wherein said compound is 
administered prior to said hepatic injury related to the viral 
infection. 
4. The method of claim 1 Wherein said compound is 
administered subsequent to said hepatic injury related to the 
viral infection. 
5. The method of claim 1 Wherein said compound is 
administered substantially concurrently With said hepatic 
injury related to the viral infection. 
6. The method of claim 1 Wherein said compound is 
administered in the formulation selected from the group 
consisting of a solution, an emulsion and a suspension. 
7. The method of claim 1 Wherein said compound is 
administered parenterally. 
8. The method of claim 1 Wherein said compound is 
administered at a concentration in the range of about 0.5 
mg/kg to about 20 mg/kg. 
9. The method of claim 1 Wherein said compound is 
administered at least until hepatic function normaliZes. 
10. A method for treating chemical toxin related hepatic 
injury in a mammal comprising administering a pharmaceu 
tically effective concentration of the peptide shoWn in SEQ 
ID NO:1 for a duration su?icient to treat the hepatic injury 
caused by the chemical toxin. 
11. The method of claim 10 Wherein the chemical toxin is 
selected from the group consisting of ethanol, lead, cad 
mium, carbon tetrachloride, and acetaminophen, and com 
binations thereof. 
